Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
31 mai 2022 08h00 HE
|
Cullinan Oncology, Inc.
Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose Confirmed overall response rate of 41%...
Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
26 mai 2022 08h45 HE
|
Cullinan Oncology, Inc.
Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical...
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
19 mai 2022 08h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies...
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
16 mai 2022 06h45 HE
|
Cullinan Oncology, Inc.
Announced U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical; updated CLN-081 data accepted for oral presentation at the American Society for Clinical...
Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
12 mai 2022 02h00 HE
|
Cullinan Oncology, Inc.
Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417 Cullinan Oncology will...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2022 17h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
27 avr. 2022 10h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies...
Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
05 avr. 2022 08h00 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 avr. 2022 16h34 HE
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients
28 mars 2022 16h01 HE
|
Cullinan Oncology, Inc.
Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety and tolerability profile observed in heavily pre-treated patients Pivotal study initiation expected...